Open access
Open access
Powered by Google Translator Translator

Pharmacology / Pharmaceutical Industry

WHO: Vaccine inequity undermining global economic recovery.

23 Jul, 2021 | 10:53h | UTC

News release: Vaccine inequity undermining global economic recovery – World Health Organization

Dashboard: Global Dashboard for Vaccine Equity

Commentaries: Urgent need for COVID-19 vaccine equity – University of Oxford AND COVID-19 Vaccine Inequity Undermines Global Economic Recovery  – Health Policy Watch

 

Commentary on Twitter (thread – click for more)

 


Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

23 Jul, 2021 | 10:51h | UTC

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet

Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

 


Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.

23 Jul, 2021 | 10:49h | UTC

SARS-CoV-2 Human Challenge Studies — Establishing the Model during an Evolving Pandemic – New England Journal of Medicine

Related: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (several texts on the subject) AND Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

 


CDC releases new guidelines for the treatment of sexually transmitted infections.

23 Jul, 2021 | 10:41h | UTC

Table of Contents: Sexually Transmitted Infections Treatment Guidelines, 2021

Guideline: Sexually Transmitted Infections Treatment Guidelines, 2021 – Centers for Disease Control and Prevention

Related (just released): WHO Guidelines for the management of symptomatic sexually transmitted infections.

 

Commentary on Twitter (thread – click for more)

 


RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

23 Jul, 2021 | 10:25h | UTC

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Dolutegravir Confirmed as Effective Second-Line HIV Therapy; Recycling Tenofovir Noninferior to Zidovudine – Medscape (free registration required)

 


Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

22 Jul, 2021 | 11:16h | UTC

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant – New England Journal of Medicine

Commentaries: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes AND Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider

Related: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. AND Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. AND Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.

 

Commentary on Twitter

 


RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.

22 Jul, 2021 | 11:08h | UTC

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology

Commentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology

 


Should children get COVID vaccines? What the science says.

22 Jul, 2021 | 11:06h | UTC

Should children get COVID vaccines? What the science says – Nature

 


Analysis finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis.

22 Jul, 2021 | 11:05h | UTC

News release: Study finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis – American Heart Association

Original study: Myocarditis with COVID-19 mRNA Vaccines – Circulation

Commentary: Myocarditis and COVID-19 Vaccines: New Review Tackles Knowns, Unknowns – TCTMD

 

Commentary on Twitter

 


Opinion | The benefits of a COVID vaccine far outweigh the small risk of treatable heart inflammation.

22 Jul, 2021 | 10:57h | UTC

The benefits of a COVID vaccine far outweigh the small risk of treatable heart inflammation – The Conversation

 


Opinion | Kids aren’t just littler adults – here’s why they need their own clinical trials for a COVID-19 vaccine.

22 Jul, 2021 | 10:55h | UTC

Kids aren’t just littler adults – here’s why they need their own clinical trials for a COVID-19 vaccine – The Conversation

 


Review: The routes of administration for acute postoperative pain medication.

22 Jul, 2021 | 10:46h | UTC

The Routes of Administration for Acute Postoperative Pain Medication – Pain and Therapy

 


WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

20 Jul, 2021 | 10:29h | UTC

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) – World Health Organization

Related Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

 


WHO and UNICEF warn of a decline in vaccinations during COVID-19.

20 Jul, 2021 | 10:27h | UTC

WHO and UNICEF warn of a decline in vaccinations during COVID-19 – World Health Organization

See also: COVID-19 pandemic leads to major backsliding on childhood vaccinations, new WHO, UNICEF data shows – World Health Organization

Related: Millions of children worldwide missed routine vaccinations during the pandemic, study suggests.

 


Experts recommend Covid jabs for some under-18s in UK – “advice is that 16 to 18-year-olds can be offered a Pfizer jab if they are in a priority group or live with someone who has a weakened immune system”.

20 Jul, 2021 | 10:15h | UTC

Commentaries: Experts recommend Covid jabs for some under-18s in UK – BBC

See report: JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years: 15 July 2021 – Joint Committee on Vaccination and Immunisation

 


ALA/ATS Response to Philip Morris International’s (PMI) Purchase of British Producer of Respiratory Treatments – “The announcement that PMI wants to acquire an inhaled medicine company is the latest reprehensible choice from a company that has profited from addicting users to its deadly products”.

20 Jul, 2021 | 10:12h | UTC

American Lung Association and the American Thoracic Society Response to Philip Morris International’s Purchase of British Producer of Respiratory Treatments – American Thoracic Society

 


RCT: Once weekly semaglutide 2.0 mg vs. 1.0 mg in patients with type 2 diabetes – Mean change in HbA1c from baseline was −2.2 percentage points with 2.0 mg vs. −1.9 percentage points with 1.0 mg; mean change in bodyweight from baseline was −6.9 kg with 2.0 mg vs. −6.0 kg with 1.0 mg.

20 Jul, 2021 | 10:09h | UTC

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial – The Lancet Endocrinology & Diabetes (link to abstract – $ for full-text)

 


Expert opinion | Bioprosthetic valves and atrial fibrillation: Direct anticoagulants or warfarin – Until conclusive data are available for patients with rheumatic heart disease and those with mechanical valves, DOAC use is not indicated in these patients.

20 Jul, 2021 | 10:06h | UTC

Bioprosthetic valves and atrial fibrillation: Direct anticoagulants or warfarin – The Journal of Thoracic and Cardiovascular Surgery

 


RCT: more data showing Azithromycin is not better than placebo in patients with Covid-19.

18 Jul, 2021 | 23:54h | UTC

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial – JAMA

Commentary: Common antibiotic no more effective than placebo in preventing COVID-19 symptoms among non-hospitalized – University of California – San Francisco

Related: RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19. (several articles on the subject)

 

Commentary on Twitter

 


Position Paper: Recommendations for the use of topical inhalant budesonide in COVID-19.

18 Jul, 2021 | 23:53h | UTC

Recommendations for use of topical inhalant budesonide in COVID-19 – HNO

Related: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 AND Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

 


CDC warns Covid-19 vaccines might not protect people who are immunocompromised – “CDC is looking into ongoing research exploring the possibility that immunocompromised could benefit from an additional dose”.

18 Jul, 2021 | 23:38h | UTC

CDC warns Covid-19 vaccines might not protect people who are immunocompromised – CNN

 


M-A: benefit-to-harm balance of statins in primary prevention of cardiovascular disease generally favorable.

18 Jul, 2021 | 23:16h | UTC

News release: New study suggests benefit-to-harm balance of statins for healthy adults ‘generally favorable’ – BMJ

Original study: Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses – The BMJ

 

Commentary on Twitter

 


Why was a major study on ivermectin for covid-19 just retracted?

16 Jul, 2021 | 11:11h | UTC

Why Was a Major Study on Ivermectin for COVID-19 Just Retracted? – Grifter Analysis and Review

See also: Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns – The Guardian AND Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19 – Nick Brown’s Blog AND Is Ivermectin for Covid-19 Based on Fraudulent Research? – Gideon M-K; Health Nerd

 

Commentary on Twitter (thread – click for more)

 


Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

16 Jul, 2021 | 11:02h | UTC

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine

Related: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 


Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

16 Jul, 2021 | 11:00h | UTC

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination – Nature Medicine

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine

Related: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.